Do you want to read an article? Please log in or register.
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
Interstitial Lung Disease
RECOMMENDED
Related content
RECOMMENDED
Further Publications
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM, SENSCIS trial investigators.
doi: 10.1016/S2213-2600(20)30330-1
RECOMMENDED
Interstitial Lung Disease
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
N Engl J Med.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, SENSCIS Trial Investigators.
doi: 10.1056/NEJMoa1903076.
PHARMA NEWS
Interstitial Lung Disease
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1
doi: 10.1056/NEJMoa1903076
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
doi: 10.1016/S2213-2600(20)30036-9.
RECOMMENDED
Interstitial Lung DiseasePneumonia
[New developments in systemic sclerosis-associated interstitial lung disease]
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Rev Med Suisse
Humair G, Daccord C, Beigelman-Aubry C, Lazor R
Interstitial Lung DiseasePulmonary Fibrosis
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
J Rheumatol.
Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E
doi: 10.3899/jrheum.151322
CoughInterstitial Lung Disease
Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases
Respirology.
Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ
doi: 10.1111/resp.13084.
RECOMMENDED
Interstitial Lung Disease
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Atienza-Mateo B, Remuzgo-Martínez S, Mora Cuesta VM, Iturbe-Fernández D, Fernández-Rozas S, Prieto-Peña D, Calderón-Goercke M, Corrales A, Blanco Rodríguez GB, Gómez-Román JJ, González-Gay MÁ, Cifrián JM
doi: 10.3390/jcm9061606.
RECOMMENDED
Interstitial Lung Disease
Systemic sclerosis-associated interstitial lung disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Perelas A, Silver RM, Arrossi AV, Highland KB
doi: 10.1016/S2213-2600(19)30480-1.